Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Generated: May 28, 2017

DrugPatentWatch Database Preview

Olanzapine - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for olanzapine and what is the scope of olanzapine freedom to operate?

is the generic ingredient in four branded drugs marketed by Teva Pharms, Ivax Pharms Inc, Aurobindo Pharma Ltd, Par Pharm, Ajanta Pharma Ltd, Torrent Pharms Llc, Qilu Pharm Co Ltd, Jubilant Generics, Dr Reddys Labs Ltd, Invagen Pharms, Torrent Pharms Ltd, Orchid Hlthcare, Sun Pharm Inds, Luitpold, Barr Labs Inc, Macleods Pharms Ltd, Lilly, Apotex Inc, Mylan Pharms Inc, Sandoz Inc, Alkem Labs Ltd, and Eli Lilly Co, and is included in thirty-three NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Olanzapine has twenty-five patent family members in twenty-three countries.

There are thirty-three drug master file entries for olanzapine. Forty-three suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for Generic Name: olanzapine

Drug Master File Entries: see list33
Suppliers / Packagers: see list43
Bulk Api Vendors: see list92
Clinical Trials: see list88
Patent Applications: see list6,198
Therapeutic Class:Bipolar Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:olanzapine at DailyMed

Pharmacology for Ingredient: olanzapine

Tentative approvals for OLANZAPINE

Applicant Application No. Strength Dosage Form
► Subscribe► Subscribe5MGTABLET; ORAL
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Invagen Pharms
TABLET, ORALLY DISINTEGRATING;ORAL203456-002Mar 16, 2016ABRXNoNo► Subscribe► Subscribe
Mylan Pharms Inc
TABLET;ORAL076866-004Apr 23, 2012ABRXNoNo► Subscribe► Subscribe
TABLET, ORALLY DISINTEGRATING;ORAL021086-001Apr 6, 2000ABRXYesYes► Subscribe► Subscribe
Mylan Pharms Inc
TABLET, ORALLY DISINTEGRATING;ORAL202285-004May 12, 2014ABRXNoNo► Subscribe► Subscribe
Par Pharm
TABLET, ORALLY DISINTEGRATING;ORAL078109-002Oct 24, 2011ABRXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Analyze global market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:

Google Plus